EVALUATION OF POPULATION PHARMACOKINETICS OF ORAL DIGOXIN IN VENOUS PLASMA
DOI:
https://doi.org/10.22159/ijap.2024v16i5.51291Keywords:
Digoxin, Population pharmacokinetics, Healthy volunteers, Two-compartment model, Liquid chromatography-mass spectrometry, PUMAS®, Dosage optimizationAbstract
Objective: Digoxin, a cardiac glycoside with extensive clinical usage, poses challenges due to its narrow therapeutic index and wide interindividual variability. Population pharmacokinetic studies in healthy individuals are scarce despite their importance in understanding drug kinetics. This study aimed to characterize the population pharmacokinetics of oral digoxin in healthy volunteers.
Methods: An open-label, single-dose pharmacokinetic study was conducted in 72 healthy Indian adults using digoxin tablets. Plasma samples were collected at various time points, and digoxin concentrations were quantified using Liquid Chromatography-Mass Spectrometry (LC-MS). Population pharmacokinetic analysis was performed using PUMAS® software, incorporating covariates such as creatinine clearance.
Results: The two-compartment model best described the data, with a population estimate of clearance (CL/F) of 12.08 l/h in the base model and 8.3 l/h in the final model. Creatinine clearance significantly influenced digoxin clearance. Goodness-of-fit plots indicated model appropriateness, and Monte Carlo simulation validated model performance.
Conclusion: This study presents a novel population pharmacokinetic model for oral digoxin in healthy individuals. The model accurately predicts digoxin pharmacokinetics and can guide dosage regimen optimization for better therapeutic outcomes. Further research should explore drug interactions and validate the model in diverse populations.
Downloads
References
Punniyakotti S, N BB. A case report on digoxin intoxication in a clinical pharmacist’s perspective. Asian J Pharm Clin Res. 2018;11(4):1-3. doi: 10.22159/ajpcr.2018.v11s4.31736.
Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J. 2017;38(27):2095-9. doi: 10.1093/eurheartj/ehw577, PMID 28065909, PMCID PMC5837211.
Sharma M, Mahindroo N. Development and validation of stability indicating rp-hplc method for determination of β-acetyldigoxin. Int J App Pharm. 2017;9(1):54-9. doi: 10.22159/ijap.2017v9i1.16076.
Angraal S, Nuti SV, Masoudi FA, Freeman JV, Murugiah K, Shah ND. Digoxin use and associated adverse events among older adults. Am J Med. 2019;132(10):1191-8. doi: 10.1016/j.amjmed.2019.04.022, PMID 31077654.
Scalese MJ, Salvatore DJ. Role of digoxin in atrial fibrillation. J Pharm Pract. 2017;30(4):434-40. doi: 10.1177/0897190016642361, PMID 27067743.
Du P, Wang A, Ma Y, Jia A, Li Y, Li X. Impact of SLCO4C1 genotypes, creatinine, and spironolactone on digoxin population pharmacokinetic variables in patients with cardiac insufficiency. Clin Ther. 2020;42(9):1799-1810.e3. doi: 10.1016/j.clinthera.2020.07.011, PMID 32798059.
Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2017;6(7):e006035. doi: 10.1161/JAHA.117.006035, PMID 28666993, PMCID PMC5586309.
Aguirre Davila L, Weber K, Bavendiek U, Bauersachs J, Wittes J, Yusuf S. Digoxin-mortality: randomized vs. observational comparison in the DIG trial. Eur Heart J. 2019;40(40):3336-41. doi: 10.1093/eurheartj/ehz395, PMID 31211324, PMCID PMC6801940.
Noviasky J, Darko W, Akajabor D, Makaron A, Miller C, Pierce DP. Chapter 6. Digoxin. In: Cohen H, editor. Casebook in clinical pharmacokinetics and drug dosing. 1st ed. New York: McGraw-Hill Education; 2016.
Komatsu T, Morita M, Miyaji F, Inomata T, Ako J, Atsuda K. Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients. J Pharm Health Care Sci. 2015;1:25. doi: 10.1186/s40780-015-0023-6, PMID 26819736, PMCID PMC4728823.
Chen R, Zou SL, Wang ML, Jiang Y, Xue H, Qian CY. Population pharmacokinetics of digoxin in elderly patients. Eur J Drug Metab Pharmacokinet. 2013;38(2):115-21. doi: 10.1007/s13318-012-0107-8, PMID 23096939.
Gong Y, Chen Y, Li Q, Li Z. Population pharmacokinetic analysis of digoxin in Chinese neonates and infants. J Pharmacol Sci. 2014;125(2):142-9. doi: 10.1254/jphs.13233fp, PMID 24837877.
Martin Suarez A, Sanchez Hernandez JG, Medina Barajas F, Perez Blanco JS, Lanao JM, Garcia Cuenllas Alvarez L. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia. Expert Rev Clin Pharmacol. 2017;10(8):911-7. doi: 10.1080/17512433.2017.1344096, PMID 28631514.
Weiss M, Li P, Roberts MS. An improved nonlinear model describing the hepatic pharmacokinetics of digoxin: evidence for two functionally different uptake systems and saturable binding. Pharm Res. 2010;27(9):1999-2007. doi: 10.1007/s11095-010-0204-9, PMID 20625800.
Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H. Population pharmacokinetic investigation of digoxin in Japanese infants and young children. J Clin Pharmacol. 2011;51(6):857-63. doi: 10.1177/0091270010374475, PMID 20592416.
Clinical Trials. Gov: Studies on Digoxin: US National Institute of Health-National Library of Medicine; 2021.
Abdel Jalil MH, Abdullah N, Alsous MM, Saleh M, Abu-Hammour K. A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. Br J Clin Pharmacol. 2020;86(7):1267-80. doi: 10.1111/bcp.14272, PMID 32153059, PMCID PMC7667574.
Abdel Jalil M, Abdullah N, Alsous M, Abu-Hammour K. Population pharmacokinetic studies of digoxin in adult patients: a systematic review. Eur J Drug Metab Pharmacokinet. 2021;46(3):325-42. doi: 10.1007/s13318-021-00672-6, PMID 33616855.
USFDA. Population pharmacokinetics guidance for industry: draft guidance (Docket Number: FDA-2019-D-2398): U.S. Department of Health and Human Services-Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2019.
WMA. Declaration of Helsinki: World Medical Association; 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects;1964/ [Last accessed on 28 Aug 2021].
ICH. Guideline for Good Clinical Practice (step 4 revision-November 2016) [international Conference on Harmonization guidelines]; 2016. p. E6(R2).
Sonawane SS, Chhajed SS, Attar SS, Kshirsagar SJ. An approach to select linear regression model in bioanalytical method validation. J Anal Sci Technol. 2019;10(1):1. doi: 10.1186/s40543-018-0160-2.
USFDA. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application: United States food and drug Adminsitration (FDA). Center for Drug Evaluation and Research (CDER); 2021.
USFDA. Bioanalytical method validation guidance for industry (Docket number: FDA-2013-D-1020). United States food and drug administration (FDA); center for drug evaluation and research (CDER). Center for Veterinary Medicine (CVM); 2018.
Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119(2):92-101. doi: 10.1002/cncy.20147, PMID 21433001.
Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783-95. doi: 10.1007/s40262-015-0236-8, PMID 25637173.
Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Ther Drug Monit. 2012;34(4):368-77. doi: 10.1097/FTD.0b013e31825c88bb, PMID 22735674, PMCID PMC3837704.
Jelliffe RW, Milman M, Schumitzky A, Bayard D, Van Guilder M. A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage. Ther Drug Monit. 2014;36(3):387-93. doi: 10.1097/FTD.0000000000000023, PMID 24492383, PMCID PMC4286255.
Hornestam B, Jerling M, Karlsson MO, Held P, DAAf Trial Group. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the digitalis in acute atrial fibrillation trial. Eur J Clin Pharmacol. 2003;58(11):747-55. doi: 10.1007/s00228-002-0553-3, PMID 12634981.
Choi SA, Yun HY, Lee ES, Shin WG. A population pharmacokinetic analysis of the influence of nutritional status of digoxin in hospitalized Korean patients. Clin Ther. 2014;36(3):389-400. doi: 10.1016/j.clinthera.2014.01.019, PMID 24612944.
Zhou XD, Gao Y, Guan Z, Li ZD, Li J. Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. Acta Pharmacol Sin. 2010;31(6):753-8. doi: 10.1038/aps.2010.51, PMID 20523346, PMCID PMC4002973.
Yukawa E, Suematu F, Yukawa M, Minemoto M, Ohdo S, Higuchi S. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. Clin Pharmacokinet. 2001;40(10):773-81. doi: 10.2165/00003088-200140100-00005, PMID 11707062.
Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol. 2003;55(6):544-51. doi: 10.1046/j.1365-2125.2003.01778.x, PMID 12814448, PMCID PMC1884248.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Sirajudeen
This work is licensed under a Creative Commons Attribution 4.0 International License.
